Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $470.9 million.

  • Legend Biotech's Non-Current Assets rose 22.07% to $470.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $470.9 million, marking a year-over-year increase of 22.07%. This contributed to the annual value of $386.2 million for FY2024, which is 10.10% up from last year.
  • As of Q3 2025, Legend Biotech's Non-Current Assets stood at $470.9 million, which was up 7.02% from $440.0 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Non-Current Assets ranged from a high of $470.9 million in Q3 2025 and a low of $140,179 during Q1 2021.
  • Its 3-year average for Non-Current Assets is $373.4 million, with a median of $373.4 million in 2024.
  • Data for Legend Biotech's Non-Current Assets shows a peak YoY spiked of 155,006.86% (in 2021) over the last 5 years.
  • Over the past 5 years, Legend Biotech's Non-Current Assets (Quarterly) stood at $169.6 million in 2021, then skyrocketed by 36.69% to $231.8 million in 2022, then spiked by 51.31% to $350.8 million in 2023, then increased by 10.10% to $386.2 million in 2024, then increased by 22.07% to $470.9 million in 2025.
  • Its last three reported values are $470.9 million in Q3 2025, $440.0 million for Q2 2025, and $396.9 million during Q1 2025.